A Phase IIb Study to Investigate the Efficacy and Tolerability of Cinaciguat (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF) (COMPOSE EARLY)

This study has been terminated.
Information provided by (Responsible Party):
ClinicalTrials.gov Identifier:
First received: February 4, 2010
Last updated: September 23, 2015
Last verified: October 2014
A placebo controlled, double-blind and randomized study to assess different doses of a new drug (BAY58-2667) given intravenously, to evaluate if it is safe and can help to improve the well-being of patients with acute decompensated heart failure.

Condition Intervention Phase
Heart Failure
Heart Decompensation
Drug: Cinaciguat (BAY58-2667)
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of BAY 58-2667 (50 µg/h, 100 µg/h, 150 µg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF) Within 12 Hours After Hospital Admission (Pulmonary Artery Catheter eg, Swan-Ganz Not Required)

Resource links provided by NLM:

Further study details as provided by Bayer:

Primary Outcome Measures:
  • Dyspnea VAS (using a visual analogue scale) [ Time Frame: 8 hours ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Dyspnea assessment (Likert Scale) [ Time Frame: up to follow-up (30 - 35 days) ] [ Designated as safety issue: No ]
  • Overall health status assessment (EQ-5D) [ Time Frame: up to follow-up (30 - 35 days) ] [ Designated as safety issue: No ]
  • Changes in the dyspnea VAS at other time points [ Time Frame: Up to follow up visit ] [ Designated as safety issue: No ]
  • Dyspnea assessment through Likert scale [ Time Frame: Up to follow up visit ] [ Designated as safety issue: No ]
  • Overall health status assessment through EQ-5D Health Questionnaire [ Time Frame: Up to the follow-up visit ] [ Designated as safety issue: No ]
  • Global clinical assessment by the physician [ Time Frame: At 8, 24, and 48 hours ] [ Designated as safety issue: No ]
  • Change in concomitant medications [ Time Frame: During the treatment ] [ Designated as safety issue: No ]
  • Safety variables [ Time Frame: Up to end of study ] [ Designated as safety issue: Yes ]
    Frequency of TEAEs (AEs were considered to be treatment emergent if they started after the start of sthe study drug infusion to up to 2 calendar days after the end of the study drug infusion); treatment-emergent serious adverse events (SAEs); deaths; evaluation of renal and cardiac function; Change in heart rate; Change in systolic and diastolic blood pressure; Laboratory parameters (including parameters related to hematology, clinical chemistry, urinalysis, and biomarkers); ECG assessment

Enrollment: 62
Study Start Date: April 2010
Study Completion Date: March 2011
Primary Completion Date: February 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1 Drug: Cinaciguat (BAY58-2667)
Infusion of 150 µg/h during 48h.
Experimental: Arm 2 Drug: Cinaciguat (BAY58-2667)
Infusion of 100 µg/h during 48h
Experimental: Arm 3 Drug: Cinaciguat (BAY58-2667)
Infusion of 50 µg/h during 48h
Placebo Comparator: Arm 4 Drug: Placebo
Infusion during 48h


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and non-pregnant, non-lactating female subjects, age >/= 18 years of age; or women without childbearing potential defined as postmenopausal women aged 55 years or older, women with bilateral tubal ligation, women with bilateral ovarectomy, and women with a hysterectomy
  • Subjects must have the clinical diagnosis of congestive heart failure (CHF) made at least three months prior to enrollment
  • Subjects must experience worsening of both of the symptoms below leading to hospitalization at the time of entry into the study: dyspnea and clinical evidence of volume overload

Exclusion Criteria:

  • Acute de-novo heart failure
  • Acute myocardial infarction and/or myocardial infarction within 30 days
  • Valvular heart disease requiring surgical intervention during the course of the study
  • Heart failure due to or associated with uncorrected primary valvular disease, malfunctioning artificial heart valve, or uncorrected congenital heart disease
  • Primary hypertrophic cardiomyopathy
  • Acute inflammatory heart disease, eg, acute myocarditis
  • Unstable angina requiring angiography
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01064037

  Show 70 Study Locations
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
No publications provided

Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT01064037     History of Changes
Other Study ID Numbers: 14836  2009-017082-39 
Study First Received: February 4, 2010
Last Updated: September 23, 2015
Health Authority: Finland: Finnish Medicines Agency
Canada: Health Canada
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: German Institute of Medical Documentation and Information
Israel: Ministry of Health
Italy: The Italian Medicines Agency
Japan: National Institute of Health Sciences
Korea: Food and Drug Administration
Hungary: National Institute of Pharmacy
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Spain: Spanish Agency of Medicines
South Africa: Human Research Ethics Committee
Poland: Ministry of Health
Czech Republic: State Institute for Drug Control
Ireland: Irish Medicines Board
United States: Food and Drug Administration

Keywords provided by Bayer:
Heart Failure

Additional relevant MeSH terms:
Heart Failure
Cardiovascular Diseases
Heart Diseases

ClinicalTrials.gov processed this record on February 11, 2016